Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a joint Heart-Kidney clinic prevent organ failure?

NCT ID NCT07835828

Disease control Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers are testing whether a specialised Cardio-Renal Clinic that brings together heart and kidney expertise can improve health for people living with both chronic kidney disease and cardiovascular disease. The trial enrolls 500 adults with established kidney and heart conditions. Participants are randomly assigned to either optimised care in the clinic, where a team reviews and adjusts guideline-based treatments, or usual care from their regular doctors. The study measures heart and kidney function, quality of life, and long-term events like death, hospitalisation, heart attack, stroke, and kidney failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a structured multidisciplinary cardio-renal care programme
What this could lead to
If it works, this could give hospitals a clear model for coordinating heart and kidney care, helping patients live longer and avoid hospital stays.
What could go wrong
The trial may show that the clinic model adds little beyond usual care, or that any benefits are hard to sustain. Coordinating care across specialties can be difficult to replicate widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Capable of giving written informed consent * Established chronic kidney disease, and at least two measurements of: 1) eGFR \<45 and \>15 mL/min/1.73 m², and/or 2) UACR \>200 mg/g, or 3) eGFR \<60 mL/min/1.73 m² and UACR \>30 mg/g. * Established cardiovascular disease, including prior acute coronary syndrome, chronic coronary syndrome, objective evidence of myocardial ischaemia, non-coronary atherosclerotic cardiovascular diase (stroke or peripheral arterial disease), heart failure with preserved ejection fraction, atrial fibrillation and/or flutter, clinically significant valvular disease, or hypertension treated with three or more antihypertensive drugs. Exclusion Criteria: * Established heart failure with reduced ejection fraction. * Diabetes type I or II * Patients receiving chronic dialysis or having of kidney transplant. * Expected life expectancy \<5 years. * Inability to understand the study procedures, comply with study requirements, or presence of any condition that, in the opinion of the research staff, may interfere with the patient's ability to participate in or complete the study. * Participation in another clinical trial with an investigational product or device that could interfere with the primary and/or secondary endpoints of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome cardiovascular disorder chronic kidney disease chronic renal failure syndrome diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Chronic kidney disease Heart failure with preserved ejection fraction (hfpef)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Research Unit, Odense University Hospital Svendborg

    Svendborg, 5700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.